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ABSTRACT 
 
Objective: The objective of this selective EBM review is to determine whether or not patients 
who have statin-associated myalgia have improved tolerability for red yeast rice (RYR) as an 
alternative treatment. 
 
Study Design: This review consists of three double blinded randomized controlled trials 
published in English in 2009, 2010, 2013. 
 
Data Sources: Three randomized, controlled, double blinded clinical trials on the tolerability of 
red yeast rice were found on PubMed and Ebsco Host.  Two trials comparing red yeast rice to 
placebo and the third trial comparing red yeast rice to pravastatin.   
 
Outcomes measured: Each of the three articles analyzed whether patients with statin-associated 
myalgia could tolerate red yeast rice in lowering serum cholesterol levels without adverse effects 
of myalgia.  The outcomes measured were based on a structured questionnaire form that assessed 
the presence of myalgia as well as a brief pain inventory short form (BPI-sf) which assessed pain 
on a scale of 0-10.   
 
Results: In Becker et al, the RYR group and placebo group did not significantly differ at baseline 
except in BPI-sf scores which was significantly higher in the placebo group P=0.026.
   
In the 
RYR group, 2 of 29 patients developed persistent intolerable myalgia and discontinued 
treatment.  In Halbert et al, 67% (14 of 21) in the RYR group reported pain whereas 68% (15 of 
22) in the pravastatin group reported pain.  The incidence of treatment discontinuation due to 
myalgia was 5% (1 of 21) in the RYR group and 9% (2 of 22) in the pravastatin group (p=0.99).  
In Verhoeven et al, 4 participants in the RYR group and 2 participants from the placebo group 
reported myalgia. 
 
Conclusions: Based on the systematic reviews of the three randomized controlled trials, it is 
inconclusive whether red yeast rice is a tolerable method for statin-intolerant patients.  It has 
been proposed that patients are able to tolerate the lower doses of monacolin K (lovastatin) than 
in statins.  However, it is unclear of the maximum threshold patients are able to tolerate.   
 
Key Words: Red yeast rice, dyslipidemia, myalgia, statin-intolerant, statin-associated myalgia  
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INTRODUCTION 
Dyslipidemia is a disorder of lipid metabolism characterized by elevated plasma 
cholesterol, triglycerides, and/or low-density lipoprotein (LDL-C), or a deficiency in high-
density lipoprotein (HDL-C).  Such cases can lead to atherosclerosis, an inflammatory condition 
caused by plaque buildup inside the arteries.
1
 At elevated levels, LDL-C tends to deposit in the 
walls of the arteries. Macrophages take up the LDL-C, triggering the release of inflammatory 
mediators that lead to the thickening and/or rupture of plaque lining the arterial walls. HDL-C 
can mitigate this problem by transporting LDL-C to the liver for processing.  Sufficient amount 
of HDL-C and/or control of LDL-C can substantially reduce cardiovascular morbidity and 
mortality.
2
 
Dyslipidemia is a major cause of coronary heart disease which is the leading cause of 
death in the United States.  An estimated 71 million (33.5%) U.S. adults aged ≥ 20 years had 
high LDL-C, but only 34 million (48.1%) were treated and 23 million (33.2%) had their LDL-C 
controlled.  Dyslipidemia can be diagnosed in anyone and has no discrimination for any 
particular race or ethnicity.
3
 The majority of patients with dyslipidemia show no signs or 
symptoms; manifestations of dyslipidemia are usually detected by routine laboratory screening.  
The causes may be genetic or secondary to diabetes, alcohol use, hypothyroidism, obesity, 
sedentary lifestyle, renal/liver disease, or drugs.
2
  The total cost of dyslipidemia associated with 
cardiovascular diseases and stroke in the U.S. was estimated to exceed $400 billion in 2006.
4
  In 
2009, 96 million visits to doctors' offices (9.2% of all visits) involved a cholesterol test.
3   
As a 
physician assistant, it is important to know the common incidence as well as risk factors for 
dyslipidemia in order to educate patient on healthy diet and exercise habits to prevent 
dyslipidemia and further complications such as coronary heart disease. 
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Patients can slow the progression of dyslipidemia by decreasing the intake of saturated 
fat, trans fats, and dietary cholesterol.  Instead, they can increase monounsaturated and 
polyunsaturated fats, antioxidants, and fiber by eating fruits and vegetables.  Alongside diet, 
patients should do some type of aerobic exercise for at least thirty minutes a day such as running 
and cycling.
1
 It is also important to encourage smoking cessation among patients who smoke 
because it can exacerbate the decrease of HDL-C.
5
  Patients also have pharmacologic options 
such as statins (HMG-CoA reductase inhibitors), niacin, bile acid sequestrants (cholestyramine, 
colesevelam, colestipol), fibric acid derivatives (gemfibrozil and clofibrate), and ezetimibe.
2
   
Statins are first-line therapy but many patients experience myalgia.  However, statin-
associated myalgia affects approximately 1.3 million people in the U.S.
6
  Therefore patients need 
to discontinue the statins.  Currently, there is no optimal treatment for patients who develop 
statin-associated myalgia.  Red yeast rice may be used as an alternative for patients.  It is a herbal 
supplement that is derived from yeast, Monascus purpureus that grows on rice.
7
 It can decrease 
LDL-C levels and has been proposed to have less adverse effects of myalgia than statins.
8
  This 
paper evaluates three double blind, randomized controlled trials which evaluate the tolerability of 
red yeast rice (RYR) as a treatment for patients with dyslipidemia who have statin-associated 
myalgia.   
OBJECTIVE  
The objective of this selective EBM review is to determine whether or not “Is red yeast 
rice tolerable in treating patients with dyslipidemia who have statin-associated myalgia?” 
METHODS 
 All three randomized, double blind controlled trials utilized for this review were selected 
because they included patients from the age of 18 to 80 who had statin-associated myalgia.
6,8
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These articles were in English and were found through the search engines, PubMed and 
EbscoHost.  Red yeast rice, dyslipidemia, statin-associated myalgia, statin-intolerant were 
keywords used in the searches.  All the articles are published in peer reviewed journals and were 
based on patient oriented outcomes.  The POEM (Patient Oriented Evidence that Matters) was 
based on statin-intolerant patients who developed myalgia and their tolerability of red yeast rice 
as an alternative treatment.  A summary of statistics used include p-values, relative risk increase 
(RRI), absolute risk increase (ARI), and number needed to harm (NNH).  
Becker et al and Verhoeven et al compared red yeast rice to an experimental group who 
received a visually matched placebo.  Halbert et al compared red yeast rice to a 40 mg 
pravastatin.  Becker et al randomly assigned 62 patients using the blockrand library of R 
programming environment with the fixed-block option to receive 600 mg capsules of red yeast 
rice or 3 placebo capsules twice daily for 24 weeks.
6
  Halbert et al randomized eligible 
participants to receive red yeast rice 4,800 mg daily or an identically appearing pravastatin 40 
mg/day for 12 weeks.
9
  Verhoeven et al included medical doctors along with their partners as the 
participants and utilized a commercially available red yeast rice that contains 1.5% Monacolin 
K.
8
  Both Becker et al and Halbert et al included patients who had resolution of myalgia when 
they discontinued statins.  In addition, both studies ordered red yeast rice capsules from Sylvan 
Bioproducts in Kittanning, Pennsylvania.
6,9
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Table 1: Demographics & Characteristics of Included Studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/
D 
Interventions 
Becker, 
2009 
Double 
Blind 
RCT 
62 21-88 
years 
old 
Patients 21 to 
80 y.o. who 
had known 
dyslipidemia 
and 
discontinued 
at least 1 statin 
because of 
myalgia 
If patients 
received a statin 
or red yeast rice 
in the month 
before random 
assignment 
 
3 Red yeast 
rice 1800 mg 
vs. placebo 
twice daily 
for 24 weeks 
Halbert, 
2010 
Double 
Blind 
RCT 
43 Trial 
did not 
include 
ages of 
pts. 
Previous statin 
associated 
myalgia 
leading to 
discontinuation 
of at least one 
statin other 
than 
pravastatin, 
with resolution 
of myalgia 
after 
discontinuation 
Statin or red 
yeast rice use 
during the 
month before 
randomization; 
History of statin-
associated 
myositis or 
rhabdomyolysis, 
and generalized 
chronic pain 
3 Red yeast 
rice 4,800 
mg daily 
(Four 600 
mg capsules 
twice daily) 
vs. 
pravastatin 
20 mg twice 
daily for 12 
weeks 
Verhoeven, 
2013 
Double 
Blind 
RCT 
52 > 18 
years 
old 
Men and 
women over 
age 18 with a 
total fasting 
cholesterol 
level above 200 
mg/dL 
Present 
treatment with 
statins and 
triglyceride 
values > 400 
mg/dL or 
changes in 
medication/food 
supplements 
which affect 
lipid levels 
during study 
2 Red yeast 
rice 
containing 
Monacolin K 
5,025 mg, 
Ubiquinone 
30 mg, 
Procyanidins 
20 mg, and 
Lecithin 300 
mg vs. 
placebo for 8 
weeks 
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Table 1 summarizes the demographics and characteristics of the inclusion and exclusion criteria 
in each study.   
OUTCOMES MEASURED 
The outcomes measured in Becker et al and Halbert et al were based on the Brief Pain 
Inventory Short Form (BPI-sf) which is a validated, widely used, self-administered questionnaire 
developed to assess the severity of pain and effect of pain on daily function from a scale of 0-10.    
0 is no pain while 10 is the worst imaginable pain.
6,9
  In Becker et al, the score reports an average 
pain over the past month and a change in scores ≥ 3 points has been cited as a clinically 
meaningful change.
   
The model for BPI-sf pain severity scores included the number of statins 
previously not tolerated as a categorical covariate.
6
  In Halbert et al, a blinded physician 
reviewed pain scales weekly on reported intolerable myalgia and whether they discontinued the 
study.
9
  At the end of study for Verhoeven et al, participants filled in a structured questionnaire 
regarding adverse events for myalgia but the article does not state that it is specifically used the 
BPI-sf method.
8
 
RESULTS  
The results were presented in dichotomous data in all three studies analyzed.  Becker et al 
had a study period of 24 weeks, Halbert et al had a study period of 12 weeks, and Verhoeven et 
al had a study period of 16 weeks.  Becker et al and Halbert et al compared red yeast rice to a 
visually similar placebo while Verhoeven et al compared red yeast rice to pravastatin.
6,8,9
   
In Becker et al, treatment adherence was assessed by self-report of average number of 
missed doses per week.  The conducted study resulted with 30 participants in the red yeast rice 
group and 29 in the placebo group.  The mean age in red yeast rice group was 60.5 years and 
61.5 years in placebo group.  A computer randomization program was used to randomize patients 
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into three groups as follows: those who had never been challenged with another statin drug, those 
who developed intolerable myalgia with a previous statin challenge, and those who had not 
developed myalgia with a different statin.  The mean number of statins received before 
intervention was 2.0 (SD 1.1) in the red yeast rice group and 1.7 (SD 0.9) in the placebo group.
6
   
Table 2:  Becker et al Brief Pain Inventory Score - Baseline, Week 12, Week 24 
 RYR Patients RYR Mean (SD) Placebo Patients  Placebo Mean (SD) 
Baseline 31 1.4 (1.9) 31 2.6 (2.2) 
Week 12 29 1.4 (1.6) 33 1.9(2.1) 
Week 24  30 1.2 (1.6) 29 2.0(2.5) 
 
Table 2 shows that the groups did not significantly differ at baseline except in BPI-sf scores 
which was significantly higher in the placebo group P=0.026.
6
     
Table 3: Estimated Difference in Myalgia between RYR and Placebo at Week 12 and 24 
 Week 12   Week 24  
 Mean (95% CI) P Value Mean (95% CI)  P Value 
BPI-sf -0.5 (-1.5 to 0.5) 0.30 -0.81 (-1.8 to 0.2) 0.120 
 
Table 3 showed insignificant differences in pain scores between groups at either week 12 or 
week 24, P=0.61.  In the RYR group, 2 of 29 patients developed persistent intolerable myalgia 
and discontinued treatment.
6
 
Table 4: Baseline Characteristics of Halbert et al Mean Brief Pain Inventory Score  
 RYR Mean ± SD Pravastatin Mean ± SD p Value 
Baseline 1.4 ± 1.9 1.1 ± 1.5 0.82 
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In the Halbert et al. study, 43 patients were eligible and agreed to a three month study.  
Table 4 shows that the red yeast rice and pravastatin groups had similar baseline characteristics.  
In the red yeast rice group, 67% (14 of 21) reported pain whereas 68% (15 of 22) in the 
pravastatin group reported pain.  The incidence of treatment discontinuation due to myalgia was 
5% (1 of 21) in the red yeast rice group and 9% (2 of 22) in the pravastatin group (p=0.99).
 
Therefore there were slightly but not significantly less participants that reported myalgia in the 
red yeast rice group than placebo.  Fisher’s exact tests were used to make comparisons between 
the treatment groups.  67% participants taking red yeast rice and 37% participants taking 
pravastatin guessed their treatment allocation correctly as an assessment of blinding.
9
 
 In the Verhoeven et al study, 54 participants were randomized through the chief 
investigator by randomly generating even for intervention and uneven for control numbers with 
no stratification for age, sex or cholesterol level.  At the end of the study, participants filled a 
structured questionnaire regarding cardiovascular risk status and eventual side effects specific to 
myalgia and other side effects.  As a result, 4 participants in the red yeast rice group and 2 
participants from the placebo group reported myalgia.  No one discontinued the study.  However, 
1 participant in the red yeast rice group expressed that experiencing myalgia was unacceptable to 
him since he was seeking for an alternative with no adverse effects of myalgia.
8
 
Table 5: CER, EER, RRI, ABI, NNH, P value Comparison Among 3 Studies  
Study  CER EER Relative Risk 
Increase 
Absolute Risk 
Increase 
Number 
Needed to 
Harm 
P value 
Becker et al 3% 7% 130% 4% 25 0.61 
Halbert et al 9% 5% -44% -4% -25 0.99 
Verhoeven et al 9% 12% 33% 3% 33 N/A 
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Table 5 summarizes the CER, EER RRI, ARI, NNH, and p-value among the three 
studies.  In Becker et al and Halbert et al studies, the p value greater than 0.05 demonstrates a 
statistically insignificant association with a high possibility that the results were due to chance.  
NNH is the number of people who would need to be treated over a specific period of time before one bad 
outcome of the treatment will occur.  In Becker et al, the positive value for NNH represents for 
every 25 participant who took red yeast rice, there was 1 more incidence of myalgia than in the 
group of participants taking the placebo.  In the Halbert et al study, analysis of the results 
showed the opposite, the negative NNH value means that for every 25 participants who took red 
yeast rice, there was 1 fewer incidence of treatment discontinuation due to myalgia than the 
group of participants taking pravastatin.  In Verhoeven et al study, a positive NNH represents for 
every 33 participants who took red yeast rice, there was 1 more incidence of myalgia than in the 
group of participants taking placebo.  When red yeast rice was compared to a placebo group, 
there was a higher incidence of myalgia than when compared to pravastatin.   
DISCUSSION  
 Red yeast rice derives from a fermentation process combining the yeast, Monascus 
purpureus with rice.  Red yeast rice has been a food staple for thousands of years in Asia.  It has 
been used for food coloring in Peking duck, red wine, rice cakes, pastries and pickled tofu during 
celebrations and festivities.  It can be grounded into fine powder to use for cooking, baking, and 
wine making in China and Japan.  In 800 AD in China, people started using red yeast rice as an 
herbal medication to build their immune system against diseases.  In addition, it has been used 
for indigestion, diarrhea, improving blood circulation, spleen and stomach health.  Monascus 
purpureus has chemical compounds called monacolin K which is the active ingredient to lower 
cholesterol.
7
 It has the same chemical structure as lovastatin, a HMG-CoA inhibitor which is 
Lam; Myalgia Incidence With Red Yeast Rice 9 
 
 
 
first-line therapy for dyslipidemia.  Therefore red yeast rice and lovastatin has the same adverse 
and interaction effects.
8
 
Red yeast rice is contraindicated in patients who are taking niacin, macrolides, 
cyclosporine, ketoconazole, and gemfibrozil because it can increase the risk of muscular 
problems.  Red yeast rice should not be taken by pregnant women because it can cause fetal CNS 
defects in the 1st trimester.  In addition, it should be used cautiously in patients with liver 
problems because it can increase liver damage.  Alcohol consumption should be avoided while 
on red yeast rice due to same exacerbation of liver disease.  Patients should use red yeast rice 
with caution because they could be at risk for rhabdomyolysis.  It has been reported that users 
have complained about other adverse effects such as GI upset, headaches, and dizziness.
7
  
Monacolin K levels per gram of labeled “active product” are not standardized and show 
substantial variability among marketed products.  It is not possible to make a comparison 
between formulations and information on labels of content may differ.  Therefore, consumers 
need to be warned that the actual content of commercially available preparations is not regulated 
which can raise issues in effectiveness and safety.
  
 FDA considers these supplements as 
unapproved drugs when they contain a specific standardized amount of lovastatin.
8
  Most 
commercially available products contain other active substances such as coenzyme Q10, 
isoflavones, probiotics, others and manufacturers commonly do not disclose levels of active 
substances in their preparations.  Doctor’s Best is voluntarily recalling lot 3121005 of Red Yeast 
Rice dietary supplement 600 mg Capsules to retail level.
10
  
 The median time of myalgia onset has been reported to be 1 to 6 months but can occur at 
any time with a range of 1 week to 48 months.  A 6 month trial in the Becker et al study was too 
short to evaluate the development of statin-associated myalgia in patients receiving red yeast 
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rice.  The study was small, short-duration, focused on a laboratory measure.
6
  Similarly, in 
Verhoeven et al, the size did not adequately assess the adverse effects of myalgia due to sample 
size.
8
 
CONCLUSION  
Based on the systematic reviews of the three randomized controlled trials, it is 
inconclusive whether red yeast rice is a tolerable method for statin-intolerant patients.  Becker et 
al and Halbert et al state that there was no increase in the incidence of myalgia in the RYR 
group.  According to Becker et al, there are probably lower dosages of monacolin K (lovastatin) 
in RYR compared to statins.  However, the exact dosage of monacolin K is unknown.
6
  Halbert 
et al states that red yeast rice contains 13 other monacolins that might act synergistically and has 
less myotoxicity.  However, this threshold is unclear since the amount of monacolin K contained 
in different red yeast rice products is unknown.
9
  In Verhoeven et al, there is a strong warning in 
the risk of myalgia due to naturally occurring statins due to its lack of regulation.
8
 
These three studies had flaws in their methods which can propose for future research.   
There are insufficient studies on the pharmacodynamics of monacolins in red yeast rice.
6
  
Therefore a characterization process is needed to differentiate among fermentation products and 
valid estimations of monacolin K present in each formulated product.  This can help clarify the 
effects of each fermentation product, ratio of monacolin K, and monacolin threshold limit in 
which patients can tolerate the red yeast rice product.
8
  If future research is done on the 
characterization process, a universal product can be developed for a possibility of FDA approval.  
In addition, a longer study should also be performed in order to determine the tolerability in 
patients because myalgia onset has been reported to be 1 to 6.3 months in statin-intolerant 
patients but it can occur at any time with a range of 1 week to 48 months.
6
  Another study 
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mentioned in Becker et al stated that patients with variants in SLCO1B1 gene were more likely 
to develop statin-associated myopathy with higher doses of statin.
6
  Therefore, further research in 
this genetic variant can be proposed in patients using red yeast rice.  
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